Australia markets closed
  • ALL ORDS

    7,709.50
    +21.50 (+0.28%)
     
  • ASX 200

    7,493.80
    +25.50 (+0.34%)
     
  • AUD/USD

    0.7118
    +0.0000 (+0.00%)
     
  • OIL

    81.57
    +0.56 (+0.69%)
     
  • GOLD

    1,925.70
    -4.30 (-0.22%)
     
  • BTC-AUD

    32,269.32
    -310.46 (-0.95%)
     
  • CMC Crypto 200

    520.36
    -6.83 (-1.29%)
     
  • AUD/EUR

    0.6535
    +0.0006 (+0.09%)
     
  • AUD/NZD

    1.0952
    -0.0008 (-0.07%)
     
  • NZX 50

    12,036.05
    +12.59 (+0.10%)
     
  • NASDAQ

    12,051.48
    +236.79 (+2.00%)
     
  • FTSE

    7,767.78
    +6.67 (+0.09%)
     
  • Dow Jones

    33,949.41
    +205.57 (+0.61%)
     
  • DAX

    15,154.29
    +21.44 (+0.14%)
     
  • Hang Seng

    22,688.90
    +122.12 (+0.54%)
     
  • NIKKEI 225

    27,382.56
    +19.81 (+0.07%)
     

Catalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

Catalyst Biosciences (NASDAQ:CBIO) Third Quarter 2022 Results

Key Financial Results

  • Net loss: US$4.88m (loss narrowed by 81% from 3Q 2021).

  • US$0.15 loss per share (improved from US$0.80 loss in 3Q 2021).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Catalyst Biosciences Earnings Insights

Looking ahead, revenue is expected to decline by 77% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 14%.

Performance of the American Biotechs industry.

The company's shares are up 2.5% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 6 warning signs for Catalyst Biosciences (of which 2 are a bit unpleasant!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here